Advertisement

Sleep Issues in Neuromuscular Junction Disorders

  • Prashant Natteru
  • Siva Pesala
  • Pradeep C. Bollu
  • Raghav Govindarajan
Chapter

Abstract

Disorders of the neuromuscular junction (NMJ) typically cause weakness. However, as a part of their full clinical presentation, patients with disorders of NMJ have a variety of sleep problems. Of them, Sleep-Related Breathing Disorders (SRBD) like sleep apnea and hypoventilation are the most common ones. Sometimes, the associated sleep disorder may be the presenting symptoms of the NMJ disorder. The associated sleep disorder can contribute to the fatigue that already exists due to the NMJ disorder. Identification of the associated sleep disorder and selection of appropriate treatment is critical to better patient outcomes. In this chapter, we go over the neuromuscular junction, the most common NMJ disorders, the associated sleep issues and discuss the therapeutic options.

Keywords

Neuromuscular junction Myasthenia gravis Lambert–Eaton myasthenic syndrome Hypoventilation Plasmapheresis Nocturnal hypoventilation Immunomodulation 

References

  1. 1.
    Kandel E, Schwartz J, Jessell T. Principles of neural science. 4th ed. New York: McGraw-Hill; 2000.Google Scholar
  2. 2.
    Magleby KI. Neuromuscular transmission. In: The anatomy, physiology, and biochemistry of muscle (Chapter 13). p. 393–418.Google Scholar
  3. 3.
    Adrian RH. The effect of internal and external potassium concentration on the membrane potential of frog muscle. J Physiol. 1956;133:631–58.CrossRefGoogle Scholar
  4. 4.
    Rowland LP, Merritt HH. Merritt’s neurology. Philadelphia: Lippincott Williams & Wilkins; 2005.Google Scholar
  5. 5.
    Somnier FE, Keiding N, Paulson OB. Epidemiology of myasthenia gravis in Denmark. A longitudinal and comprehensive population survey. Arch Neurol. 1991;48:733–9.CrossRefGoogle Scholar
  6. 6.
    Phillips LH, Torner JC, Anderson MS, Cox GM. The epidemiology of myasthenia gravis in central and western Virginia. Neurology. 1992;42:1888–93.CrossRefGoogle Scholar
  7. 7.
    Vincent A, McConville J, Farrugia ME, Newsom-Davis J. Seronegative myasthenia gravis. Semin Neurol. 2004;24:125–33.CrossRefGoogle Scholar
  8. 8.
    Ulane CM, Lewis PR. Merritt’s neurology. Philadelphia: Lippincott Williams & Wilkins; 2015.Google Scholar
  9. 9.
    Cohen MS, Younger D. Aspects of the natural history of myasthenia gravis: crisis and death. Ann N Y Acad Sci. 1981;377:670–7.CrossRefGoogle Scholar
  10. 10.
    Wittbrodt ET. Drugs and myasthenia gravis. An update. Arch Intern Med. 1997;157:399–408.CrossRefGoogle Scholar
  11. 11.
    Plauché WC. Myasthenia gravis in pregnancy: an update. Am J Obstet Gynecol. 1979;135:691–7.CrossRefGoogle Scholar
  12. 12.
    Crain SM, Bornstein MB, Lennon VA. Depression of complex bioelectric discharges in cultured cerebral tissue cultures by thermolabile dependent serum factors. Exp Neurol. 1975;49:330–5.CrossRefGoogle Scholar
  13. 13.
    Kuks JBM. Clinical presentation and epidemiology of myasthenia gravis. Myasthenia gravis and related disorders. New York: Springer; 2008.  https://doi.org/10.1007/978-1-59745-156-7_5.CrossRefGoogle Scholar
  14. 14.
    Oosterhuis HJGH. Myasthenia gravis. Edinburgh: Churchill Livingstone; 1984.Google Scholar
  15. 15.
    Palace J, Newsom-Davis J, Lecky BA. Randomized doubleblind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia gravis study group. Neurology. 1998;50(6):1778–83.CrossRefGoogle Scholar
  16. 16.
    Myasthenia Gravis Clinical Study Group. A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. J Neurol Neurosurg Psychiatry. 1993;56(11):1157–63.CrossRefGoogle Scholar
  17. 17.
    Tindall RS, Rollins JA, Phillips JT, et al. Preliminary results of a double-blind, randomized, placebo controlled trial of cyclosporine in myasthenia gravis. N Engl J Med. 1987;316(12):719–24.  https://doi.org/10.1056/NEJM198703193161205.CrossRefPubMedGoogle Scholar
  18. 18.
    Tindall RS, Phillips JT, Rollins JA, et al. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci. 1993;681:539–51.CrossRefGoogle Scholar
  19. 19.
    Meriggioli MN, Ciafaloni E, Al-Hayk KA, et al. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology. 2003;61(10):1438–40.CrossRefGoogle Scholar
  20. 20.
    Sanders DB, Hart IK, Mantegazza R, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology. 2008;71(6):400–6.  https://doi.org/10.1212/01.wnl.0000312374.95186.cc.CrossRefPubMedGoogle Scholar
  21. 21.
    Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology. 2008;71(6):394–9.  https://doi.org/10.1212/01.wnl.0000312373.67493.7f.CrossRefGoogle Scholar
  22. 22.
    Nagane Y, Utsugisawa K, Obara D, et al. Efficacy of lowdose FK506 in the treatment of myasthenia gravis—a randomized pilot study. Eur Neurol. 2005;53(3):146–50.  https://doi.org/10.1159/000085833.CrossRefPubMedGoogle Scholar
  23. 23.
    Gajdos P, Tranchant C, Clair B, et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. Arch Neurol. 2005;62(11):1689–93.  https://doi.org/10.1001/archneur.62.11.1689.CrossRefPubMedGoogle Scholar
  24. 24.
    Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology. 2007;68(11):837–41.  https://doi.org/10.1212/01.wnl.0000256698.69121.45.CrossRefPubMedGoogle Scholar
  25. 25.
    Barth D, Nabavi Nouri M, Ng E, et al. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011;76(23):2017–23.  https://doi.org/10.1212/WNL.0b013e31821e5505.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    De Feo LG, Schottlender J, Martelli NA, et al. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve. 2002;26(1):31–6.  https://doi.org/10.1002/mus.10133.CrossRefPubMedGoogle Scholar
  27. 27.
    Gutmann L, Phillips LH, Gutmann L. Trends in the association of Lambert-Eaton myasthenic syndrome with carcinoma. Neurology. 1992;42:848–50.CrossRefGoogle Scholar
  28. 28.
    Argov Z, Shapira Y, Averbuch-Heller L, Wirguin I. Lambert-Eaton myasthenic syndrome (LES) in association with lymphoproliferative disorders. Muscle Nerve. 1995;18:715–9.CrossRefGoogle Scholar
  29. 29.
    Burns TM, Juel VC, Sanders DB, Phillips LH. Neuroendocrine lung tumors and disorders of the neuromuscular junction. Neurology. 1999;52:1490–1.CrossRefGoogle Scholar
  30. 30.
    Collins DR, Connolly S, Burns M, Offiah L, Grainger R, Walsh JB. Lambert-Eaton myasthenic syndrome in association with transitional cell carcinoma: a previously unrecognized association. Urology. 1999;54:162.CrossRefGoogle Scholar
  31. 31.
    Dalmau J, Gultekin HS, Posner JB. Paraneoplastic neurologic syndromes: pathogenesis and physiopathology. Brain Pathol. 1999;9:275–84.CrossRefGoogle Scholar
  32. 32.
    Oyaizu T, Okada Y, Sagawa M, Yamakawa K, Kuroda H, Fujihara K, Itoyama Y, Tanita T, Motomura M, Kondo T. Lambert-Eaton myasthenic syndrome associated with an anterior mediastinal small cell carcinoma. J Thorac Cardiovasc Surg. 2001;121:1005–6.CrossRefGoogle Scholar
  33. 33.
    O’Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain. 1988;111:577–96.CrossRefGoogle Scholar
  34. 34.
    Waterman SA, Lang B, Newsom-Davis J. Effect of Lambert-Eaton myasthenic syndrome antibodies on autonomic neurons in the mouse. Ann Neurol. 1997;42:147–56.CrossRefGoogle Scholar
  35. 35.
    Harper CM. Electrodiagnosis of endplate disease. In: Engel AG, editor. Myasthenia gravis and myasthenic syndromes. New York: Oxford Press; 1999. p. 65–86.Google Scholar
  36. 36.
    Lennon VA. Serological diagnosis of myasthenia gravis and the Lambert-Eaton myasthenic syndrome. In: Lisak R, editor. Handbook of myasthenia gravis, chapter 7. New York: Marcel Dekker; 1994. p. 149–64.Google Scholar
  37. 37.
    Lennon VA, Kryzer TJ, Greismann GE, O’Suilleabhain PE, Windebank AJ, Woppmann A, Miljanich GP, Lambert E. Calcium channel antibodies in the Lambert-Eaton myasthenic syndrome and other paraneoplastic syndromes. N Engl J Med. 1995;332:1467–74.CrossRefGoogle Scholar
  38. 38.
    Vernino S, Adamski J, Kryzer TJ, Lennon VA. Neuronal nicotinic AChR antibody in subacute autonomic neuropathy and cancer-related syndromes. Neurology. 1998;50:1806–13.CrossRefGoogle Scholar
  39. 39.
    Lennon VA. Serologic profile of myasthenia gravis and distinction from Lambert-Eaton myasthenic syndrome. Neurology. 1997;48(Suppl 5):S23–7.CrossRefGoogle Scholar
  40. 40.
    Maddison P, Newsom-Davis J, Mills KR, Souhami RL. Favorable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet. 1999;353:117–8.CrossRefGoogle Scholar
  41. 41.
    Kamenskaya MA, Elmqvist D, Thesleff S. Guanidine and neuromuscular transmission. II. Effect on transmitter release in response to repetitive nerve stimulation. Arch Neurol. 1975;32:510–8.CrossRefGoogle Scholar
  42. 42.
    Oh SJ, Kim DS, Head TC, Claussen GC. Low dose guanidine and pyridostigmine: relatively safe and effective longterm symptomatic therapy in Lambert-Eaton myasthenic syndrome. Muscle Nerve. 1997;20:1146–52.CrossRefGoogle Scholar
  43. 43.
    Silbert PL, Hankey GJ, Barr AL. Successful alternate day guanidine therapy following guanidine-induced neutropenia in the Lambert-Eaton myasthenic syndrome. Muscle Nerve. 1990;13:360–1.CrossRefGoogle Scholar
  44. 44.
    Cherington M. Guanidine and germine in Eaton-Lambert syndrome. Neurology. 1976;26:944–6.CrossRefGoogle Scholar
  45. 45.
    Blumhardt LD, Joekes AM, Marshall J, Philalithis PE. Guanidine treatment and impaired renal function in the Eaton-Lambert syndrome. Br Med J. 1977;1:946–7.CrossRefGoogle Scholar
  46. 46.
    Harper CM, McEvoy KM, Windebank AJ, Daube JR. Effect of 3,4-diaminopyridine on neuromuscular transmission in patients with Lambert-Eaton myasthenic syndrome. Electroencephalogr Clin Neurophysiol. 1990;75:557.CrossRefGoogle Scholar
  47. 47.
    Kim DS, Claussen GC, Oh SJ. Single-fiber electromyography improvement with 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Muscle Nerve. 1998;21:1107–8.CrossRefGoogle Scholar
  48. 48.
    Boerma CE, Rommes JH, van Leeuwen RB, Bakker J. Cardiac arrest following an iatrogenic 3,4-diaminopyridine intoxication in a patient with Lambert-Eaton myasthenic syndrome. Clin Toxicol. 1995;33:249–51.Google Scholar
  49. 49.
    Sanders D, Howard F Jr. Disorders of neuromuscular transmission. In: Bradley W, Daroff R, Fenichel G, Marsden C, editors. Neurology in clinical practice. Boston: Butterworth Heinemann; 2000. p. 2167–85.Google Scholar
  50. 50.
    MacDonald KL, Rutherford SM, Friedman SM, Dieter JA, Kaye BR, McKinley GF, Tenney JH, Cohen ML. Botulism and botulism-like illness in chronic drug users. Ann Intern Med. 1985;102:616–8.CrossRefGoogle Scholar
  51. 51.
    Pickett J, Berg B, Chaplin E, Brunstetter-Shafer M. Syndrome of botulism in infancy: clinical and electrophysiologic study. N Engl J Med. 1976;295:770–92.CrossRefGoogle Scholar
  52. 52.
    Chia JK, Clark JB, Ryan CA, Pollack M. Botulism in an adult associated with food-borne intestinal infection with Clostridium botulinum. N Engl J Med. 1986;315:239–41.CrossRefGoogle Scholar
  53. 53.
    Dowell VR Jr, McCroskey LM, Hatheway CL, Lombard GL, Hughes JM, Merson MH. Coproexamination for botulinal toxin and clostridium botulinum. A new procedure for laboratory diagnosis of botulism. JAMA. 1977;238:1829–32.CrossRefGoogle Scholar
  54. 54.
    Griffin PM, Hatheway CL, Rosenbaum RB, Sokolow R. Endogenous antibody production to botulinum toxin in an adult with intestinal colonization botulism and underlying Crohn’s disease. J Infect Dis. 1997;175:633–7.CrossRefGoogle Scholar
  55. 55.
    Bhat S, Gupta D, Chokroverty S. Sleep disorders in neuromuscular diseases. Neurol Clin. 2012;30:1359–87.CrossRefGoogle Scholar
  56. 56.
    Furuta H, Kaneda R, Kosaka K, et al. Epworth sleepiness scale and sleep studies in patients with obstructive sleep apnea syndrome. Psychiatry Clin Neurosci. 1999;53(2):301.CrossRefGoogle Scholar
  57. 57.
    Chokroverty S. Sleep and breathing in neuromuscular disorders. Handb Clin Neurol. 2011;99:1087–108.CrossRefGoogle Scholar
  58. 58.
    Fernandes Oliveira E, Nacif SR, Alves Pereira N, et al. Sleep disorders in patients with myasthenia gravis: a systematic review. J Phys Ther Sci. 2015;27(6):2013–8.  https://doi.org/10.1589/jpts.27.2013.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Manni R, Piccolo G, Sartori I, et al. Breathing during sleep in myasthenia gravis. Ital J Neurol Sci. 1995;16(9):589–94.CrossRefGoogle Scholar
  60. 60.
    Fermin AM, Afzal U, Culebras A. Sleep in neuromuscular diseases. Sleep Med Clin. 2016;11(1):53–64. Online publication date: 1-Mar-2016.CrossRefGoogle Scholar
  61. 61.
    Papazian O. Rapid eye movement sleep alterations in myasthenia gravis. Neurology. 1976;26:311–6.CrossRefGoogle Scholar
  62. 62.
    Mennuni G, Morante MT, Di Meo L, et al. [Myasthenia and sleep]. Schweiz Arch Neurol Neurochir Psychiatr. 1983;133:193–203.Google Scholar
  63. 63.
    Stepansky R, Weber G, Zeitlhofer J. Sleep apnea and cognitive dysfunction in myasthenia gravis. Acta Med Austriaca. 1997;24:128–31.PubMedGoogle Scholar
  64. 64.
    Amino A, Shiozawa Z, Nagasaka T, et al. Sleep apnoea in well-controlled myasthenia gravis and the effect of thymectomy. J Neurol. 1998;245:77–80.CrossRefGoogle Scholar
  65. 65.
    Nicolle MW, Rask S, Koopman WJ, et al. Sleep apnea in patients with myasthenia gravis. Neurology. 2006;67:140–2.CrossRefGoogle Scholar
  66. 66.
    Happe S, Klösch G, Zeitlhofer J. Perception of dreams and subjective sleep quality in patients with myasthenia gravis. Neuropsychobiology. 2004;50:21–7.CrossRefGoogle Scholar
  67. 67.
    Quera-Salva MA, Guilleminault C, Chevret S, et al. Breathing disorders during sleep in myasthenia gravis. Ann Neurol. 1992;31:86–92.CrossRefGoogle Scholar
  68. 68.
    Elsais A, Wyller VB, Loge JH, et al. Fatigue in myasthenia gravis: is it more than muscular weakness? BMC Neurol. 2013;13:132.CrossRefGoogle Scholar
  69. 69.
    Kassardjian CD, Murray BJ, Kokokyi S, et al. Effects of napping on neuromuscular fatigue in myasthenia gravis. Muscle Nerve. 2013;48:816–8.CrossRefGoogle Scholar
  70. 70.
    Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;42(2):101–19.CrossRefGoogle Scholar
  71. 71.
    Ondo WG. Restless legs syndrome. Neurol Clin. 2009;27(3):779–99.CrossRefGoogle Scholar
  72. 72.
    Sieminski M, Bilińska M, Nyka WM. Increased frequency of restless legs syndrome in myasthenia gravis. Eur Neurol. 2012;68:166–70.CrossRefGoogle Scholar
  73. 73.
    Kimura J. Electrodiagnosis in diseases of the nerve and muscle, principles and practice. 3rd ed. Oxford: New York; 2001.Google Scholar
  74. 74.
    Steier J, Jolley CJ, Seymour J, et al. Screening for sleep-disordered breathing in neuromuscular disease using a questionnaire for symptoms associated with diaphragm paralysis. Eur Respir J. 2011;37(2):400–5.CrossRefGoogle Scholar
  75. 75.
    Naseer S, Kolade VO, Idrees S, et al. Improvement in ocular myasthenia gravis during CPAP therapy for sleep apnea. Tenn Med. 2012;105(9):33–4.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Prashant Natteru
    • 1
  • Siva Pesala
    • 2
  • Pradeep C. Bollu
    • 2
  • Raghav Govindarajan
    • 2
  1. 1.Department of NeurologyUniversity of Mississippi Medical CenterJacksonUSA
  2. 2.Department of NeurologyUniversity of MissouriColumbiaUSA

Personalised recommendations